Modality
Peptide
MOA
JAK1/2i
Target
MET
Pathway
Tau
WM
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ Sep 2030
Phase 2Current
NCT05476267
1,086 pts·WM
2018-09→2030-01·Terminated
NCT03490488
1,038 pts·WM
2018-08→2030-09·Completed
2,124 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-01-183.8y awayPh3 Readout· WM
2030-09-264.5y awayPh3 Readout· WM
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2030-01-18 · 3.8y away
WM
Ph3 Readout
2030-09-26 · 4.5y away
WM
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05476267 | Phase 2/3 | WM | Terminated | 1086 | PASI75 |
| NCT03490488 | Phase 2/3 | WM | Completed | 1038 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET |